Brolucizumab 120 mg/mL Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 120 mg/mL
Reference Brands: Beovu (USA/EU)
Category: Opthalmology
Brolucizumab is a humanized monoclonal single-chain antibody fragment (scFv) that targets vascular endothelial growth factor A (VEGF-A). It is used to treat neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
Product Description:
Brolucizumab is an advanced anti-vascular endothelial growth factor (anti-VEGF) therapy used for the treatment of neovascular (wet) age-related macular degeneration (nAMD), a serious eye condition that can lead to progressive vision loss. It is marketed under the brand name Beovu and developed by Novartis. Brolucizumab works by inhibiting VEGF-A, a protein responsible for the growth of abnormal blood vessels and fluid leakage in the retina. By blocking this pathway, the medicine helps reduce retinal swelling, improve visual outcomes, and slow disease progression.
The drug received approval from the United States Food and Drug Administration (US-FDA) in October 2019 for the treatment of nAMD, followed by approval in the European Union in February 2020. Its approval was supported by two major Phase 3 clinical trials, HAWK and HARRIER, which demonstrated the drug’s efficacy and safety with extended dosing intervals of every 8 to 12 weeks in many patients after the loading phase. Brolucizumab is administered as an intravitreal injection by an ophthalmology specialist and is designed to provide durable disease control with fewer injections compared to some earlier anti-VEGF therapies.
Brolucizumab — third party manufacturing & bulk supply
Brolucizumab 120 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Brolucizumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Brolucizumab →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Brolucizumab is used to treat eye conditions that can lead to vision loss, mainly neovascular (wet) age-related macular degeneration and diabetic macular edema. It works by reducing abnormal blood vessel growth and fluid leakage in the retina, which helps improve or maintain vision in affected patients.
Brolucizumab is a humanized single-chain antibody fragment that targets vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, it prevents the formation of abnormal blood vessels and reduces swelling in the retina. It is given as an intravitreal injection directly into the eye.
The most widely known trade name of brolucizumab is Beovu. In some markets, including India, it is also available under the brand Pagenax.
Brolucizumab is developed and marketed by Novartis, a global pharmaceutical company specializing in innovative medicines including ophthalmology treatments.
The generic name of the medicine is brolucizumab.
The primary brand name is Beovu, and in some regions it is also marketed as Pagenax.
Brolucizumab is manufactured through Novartis’ global biologics manufacturing network, with production and supply managed across facilities that serve the United States, Europe, and other approved international markets.
Related Products
Artificial Tears
Strength:
0.3% to 1%
Form: Eye Drops/ Eye Gel/ Eye ointment
Reference Brands: Refresh Tears (USA/LATAM), Hylo-Tear (EU), Refresh Liquigel (India)
View Details
Tetrahydrozoline Hydrochloride
Strength:
0.05%
Form: Eye Drops
Reference Brands: Visine (USA/EU / LATAM), Ocuvis (India)
View Details
Quick Response Guaranteed | Verified Suppliers
